{"id":"W2576914903","doi":"10.1182/blood.v120.21.1637.1637","title":"Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Rituximab; Medicine; Tolerability; Fludarabine; Cyclophosphamide; Internal medicine; Population; Phases of clinical research; Pharmacokinetics; Oncology; Gastroenterology; Adverse effect; Pharmacology; Clinical trial; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001337457,0.0007677173,0.001548843,0.0002877896,0.0002740779,0.0008166292,0.0005037013,0.0008386852,0.002280515],"category_scores_gemma":[0.0008474039,0.0005073033,0.001148065,0.0003383665,0.0006409795,0.0005633587,0.0002998484,0.002366579,0.0006100705],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006400812,"about_ca_system_score_gemma":0.001216456,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009821876,"about_ca_topic_score_gemma":0.002309331,"domain_scores_codex":[0.9995686,0.0002234204,0.00002529248,0.00005842587,0.00004932999,0.00007488928],"domain_scores_gemma":[0.9994072,0.0001385418,0.000123855,0.00004181896,0.00003158003,0.0002570223],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5950797,0.07302334,0.008295543,0.0009786333,0.001729382,0.0003376859,0.0003536407,0.001831962,0.06077001,0.0002020873,0.002451106,0.2549469],"study_design_scores_gemma":[0.4196839,0.5624009,0.01174739,0.00004053228,0.0005749784,0.0002268809,0.00004593873,0.0008021685,0.002620899,0.00006687291,0.001767322,0.00002231591],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943107,0.002874097,0.0003855849,0.0003164813,0.00006525749,0.0007962458,0.0002190977,0.00006532861,0.0009672232],"genre_scores_gemma":[0.9936084,0.002310357,0.00101355,0.0005887023,0.0001308512,0.000677757,0.0006408221,0.00001762826,0.001012067],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002280515,"threshold_uncertainty_score":0.007629037,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01674751559810482,"score_gpt":0.3080953956362656,"score_spread":0.2913478800381608,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}